Live Analysis:
AbbVie Inc. (ABBV) is currently priced at $227.73, showing a price increase of $2.96 (1.32%) from the previous close at $224.77. Trading volume is notable, reaching $4 million, representing a 62.43% increase compared to the average volume.
Earnings Overview:
AbbVie's latest quarterly earnings report is set for Tuesday, April 28th, with a consensus estimate EPS of 2.69.
Dividends:
The company offers a forward dividend yield of 3.04%, with a dividend per share MRQ of $1.73 and a year-over-year increase to $6.74.
Cash Flow:
AbbVie reports a healthy cash flow with free cash flow of $3.56 billion and a net change in cash of $4.16 billion.
Income Statement:
Revealing a revenue of $15 billion, AbbVie maintains a gross profit of $10.78 billion and an operating income of $4.73 billion.
Ratios:
Key ratios indicate a gross profit margin of 71.88%, operating profit margin of 31.56%, and a return on equity of 2.54.
Balance Sheet:
The balance sheet showcases total assets of $136.46 billion, total liabilities of $108.96 billion, and net debt at $63.47 billion.
This comprehensive overview reflects AbbVie's strong financial standing and performance in the current market session.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.